Compare OMEX & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OMEX | PLRX |
|---|---|---|
| Founded | 1986 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.6M | 74.9M |
| IPO Year | 2024 | 2020 |
| Metric | OMEX | PLRX |
|---|---|---|
| Price | $0.90 | $1.14 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.67 |
| AVG Volume (30 Days) | ★ 678.9K | 440.2K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.97 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,327.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.74 | $1.09 |
| 52 Week High | $4.43 | $1.95 |
| Indicator | OMEX | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 37.12 | 45.61 |
| Support Level | $0.87 | $1.14 |
| Resistance Level | $1.72 | $1.37 |
| Average True Range (ATR) | 0.08 | 0.05 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 6.16 | 28.57 |
Odyssey Marine Exploration Inc is a deep-ocean exploration company. It discovers, validates, and develops high-value seafloor mineral resources and provides specialized mineral exploration, project development, and marine services to its clients. The company's subsea project portfolio contains multiple projects in various stages of development, such as the Phosagmex Project, a rich deposit of phosphate sands located seventy-ninety meters deep within the Mexican EEZ; two polymetallic nodule exploration license holders in the Cook Islands' EEZ; the Lihir Gold Project, a subsea area that contains several prospective gold exploration targets located in the Papua New Guinea Exclusive Economic Zone (EEZ); and others.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.